Advancement insights in cancer vaccines: mechanisms, types, and clinical applications
- 7 March 2025
- journal article
- review article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-19
Abstract
Immunotherapy can treat cancer by boosting the immune system to mark and destroy cancer cells. Cancer vaccine is a promising therapeutic strategy in immunotherapy. Cancer vaccines are divided into four groups according to different preparation techniques: cell-based vaccine, virus-based vaccine, peptide-based vaccine, and nucleic acid-based vaccine. Cancer vaccines can be given with traditional treatments or another immunotherapy to give better results and overcome tumor resistance. The cancer vaccine is a promising immunotherapy that could stimulate the immune response to kill cancer cells and create immune surveillance. However, much work is still needed to identify neoantigens, optimize the vaccination platform, and develop combination therapy to improve the efficacy of immunotherapy. This review highlights the mechanism of action of cancer vaccines, the main four groups of cancer vaccines regarding their development, research progress, and clinical applications, and how to assess immune response following cancer vaccination.Keywords
This publication has 90 references indexed in Scilit:
- T-Regulatory Cells: Key Players in Tumor Immune Escape and AngiogenesisCancer Research, 2012
- Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancerHuman Vaccines & Immunotherapeutics, 2012
- Translating Tumor Antigens into Cancer VaccinesClinical and Vaccine Immunology, 2011
- Methods to measure T-cell responsesExpert Review of Vaccines, 2010
- Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentationEuropean Journal of Immunology, 2008
- A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate CancerJournal of Translational Medicine, 2006
- Vaccines in cancer: GVAX®, a GM-CSF gene vaccineExpert Review of Vaccines, 2005
- First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host ResponseThe Journal of Infectious Diseases, 1998
- Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.1996
- Prospectively randomized trial of adjuvant active‐specific immunotherapy for human colorectal cancerCancer, 1985